An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment
Author:
Affiliation:
1. United Therapeutics Corporation; Research Triangle Park NC USA
2. Orlando Clinical Research Center; Orlando FL USA
3. Pharsight - A Certara Company; Montreal Quebec Canada
Funder
United Therapeutics Corp.
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12094/fullpdf
Reference11 articles.
1. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension;Barst;N Engl J Med,1996
2. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial;Badesch;Ann Intern Med,2000
3. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial;Simonneau;Am J Respir Crit Care Med,2002
4. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension;McLaughlin;J Cardiovasc Pharmacol,2003
5. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open label, 12-week trial;Tapson;Chest,2006
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Physiologically based pharmacokinetic modelling of treprostinil after intravenous injection and extended‐release oral tablet administration in healthy volunteers: An extrapolation to other patient populations including patients with hepatic impairment;British Journal of Clinical Pharmacology;2021-07-23
2. Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension;Journal of Cardiovascular Pharmacology;2020-07
3. Treatment Barriers in Portopulmonary Hypertension;Hepatology;2018-12-18
4. Diagnosis, Treatment, and Management of Orthotopic Liver Transplant Candidates With Portopulmonary Hypertension;Cardiology in Review;2018-07
5. Pharmacological Considerations in Acute and Chronic Liver Disease;Hepatic Critical Care;2018
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3